{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:13Z","timestamp":1792896913260,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2020,2,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The current study was conducted to evaluate the efficacy and safety of pembrolizumab\u2010mediated programmed cell death protein 1 inhibition plus radiotherapy (RT) in patients with metastatic triple\u2010negative breast cancer who were unselected for programmed death\u2010ligand 1 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The current study was a single\u2010arm, Simon 2\u2010stage, phase 2 clinical trial that enrolled a total of 17 patients with a median age of 52\u00a0years (range, 37\u201073\u00a0years). An RT dose of 3000 centigrays (cGy)\u00a0was delivered in 5 daily fractions. Pembrolizumab was administered intravenously at a dose of 200\u00a0mg within 3\u00a0days of the first RT fraction, and then every 3\u00a0weeks \u00b1 3\u00a0days until disease progression. The median follow\u2010up was 34.5\u00a0weeks (range, 2.1\u2010108.3\u00a0weeks). The primary endpoint of the current study was the overall response rate (ORR) at week 13 in patients with unirradiated lesions measured using Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Secondary endpoints included safety and progression\u2010free survival. Exploratory objectives were to identify biomarkers predictive of ORR and progression\u2010free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ORR for the entire cohort was 17.6% (3 of 17 patients; 95% CI, 4.7%\u201044.2%), with 3 complete responses (CRs), 1 case of stable disease, and 13 cases of progressive disease. Eight patients died prior to week 13 due to disease progression. Among the 9 women assessed using RECIST version 1.1 at week 13, 3 (33%) achieved a CR, with a 100% reduction in tumor volume outside of the irradiated portal. The CRs were durable for 18\u00a0weeks, 20\u00a0weeks, and 108\u00a0weeks, respectively. The most common grade 1 to 2 toxicity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0) was dermatitis (29%). Four grade 3 adverse events were attributed to pembrolizumab: fatigue, lymphopenia, and infection. No were no grade 4 adverse events or treatment\u2010related deaths reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of pembrolizumab and RT was found to be safe and demonstrated encouraging activity in patients with poor\u2010prognosis, metastatic, triple\u2010negative breast cancer who were unselected for programmed death\u2010ligand 1 expression. Larger clinical trials of checkpoint blockade plus RT with predictive biomarkers of response are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.32599","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T08:34:01Z","timestamp":1574238841000},"page":"850-860","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":191,"title":["A phase 2 clinical trial\u202fassessing the\u202fefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple\u2010negative breast cancer"],"prefix":"10.1002","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6812-4187","authenticated-orcid":false,"given":"Alice Y.","family":"Ho","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany B.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon N.","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zishuo I.","family":"Hu","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-3751","authenticated-orcid":false,"given":"Ayca","family":"Gucalp","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza","family":"Lebron\u2010Zapata","sequence":"additional","affiliation":[{"name":"Department of Radiology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Y.","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pathology Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Kallman","sequence":"additional","affiliation":[{"name":"Department of Radiology Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"D'Agnolo","sequence":"additional","affiliation":[{"name":"Department of Radiology Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Massachusetts General Hospital Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"McArthur","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Medicine Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2009.n.005"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11154"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0127"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1061"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4224"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.1008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2756"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1719"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9023"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2820"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.2229"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.21478"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.7.10.6540"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2011.03.007"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1523"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1060391"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.777003"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5069"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx029"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.166629"},{"key":"e_1_2_8_29_1","unstructured":"KokM VoorwerkL HorlingsH SikorskaK. Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): final response data stage I and first translational data. Paper presented at: 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1\u20105 2018;Chicago Illinois."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"issue":"13","key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1538-7445.AM2017-2986","article-title":"Atezolizumab in metastatic TNBC (mTNBC): long\u2010term clinical outcomes and biomarker analyses [abstract]","volume":"77","author":"Schmid P","year":"2017","journal-title":"Cancer Res"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8931"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4537-5"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_2_8_35_1","first-page":"987","article-title":"Atezolizumab and nab\u2010paclitaxel in advanced triple\u2010negative breast cancer. Reply","volume":"380","author":"Schmid P","year":"2019","journal-title":"N Engl J Med"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.04.038"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.1012"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157164"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.32599","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32599","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32599","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:35:17Z","timestamp":1760279717000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2,15]]}},"alternative-id":["10.1002\/cncr.32599"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32599","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"2019-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}